Core Viewpoint - Getein Biotech, Inc. reported a decline in revenue and net profit for the first half of 2025, with a focus on maintaining a strong position in the in vitro diagnostics (IVD) market despite challenges [1][2]. Financial Performance - Revenue for the first half of 2025 was approximately RMB 512.69 million, a decrease of 17% compared to RMB 617.67 million in the same period last year [2]. - Total profit for the period was RMB 110.53 million, down 33.49% from RMB 166.18 million year-on-year [2]. - Net profit attributable to shareholders was RMB 108.81 million, reflecting a 25.88% decline from RMB 146.81 million in the previous year [2]. - The company proposed a cash dividend of RMB 0.9 per 10 shares, amounting to a total distribution of approximately RMB 45.64 million, which represents 41.95% of the net profit for the period [1]. Industry Overview - The global IVD market is projected to reach USD 109.2 billion in 2024 and is expected to grow significantly, driven by factors such as policy support, aging populations, and rising chronic disease rates [4][5]. - In China, the IVD market has experienced rapid growth due to increased healthcare demand, improved medical insurance coverage, and advancements in domestic technology [5][6]. - The POCT segment is one of the fastest-growing areas in the IVD market, driven by the convenience and speed of testing, with significant potential for future growth [6]. Company Strategy and Product Development - The company has established eight major technology platforms, including POCT, chemiluminescence, biochemical detection, and molecular detection, to meet clinical needs [7][9]. - Getein has transitioned from a single POCT product line to a diverse range of products, including high-throughput and automated solutions for various healthcare settings [9][10]. - The company is actively expanding its market presence both domestically and internationally, with a focus on building a robust sales network through partnerships with over 3,000 distributors [12][13]. Regulatory and Market Position - As of June 30, 2025, the company held a total of 3,245 product registration certificates, with 460 of these being domestic [11][12]. - Getein's products are now available in 67 countries and regions, with a total of 2,785 product import licenses obtained [12][11]. - The company is committed to maintaining high-quality standards in production, adhering to ISO13485 quality management systems, and ensuring compliance with medical device regulations [14][15].

Core Viewpoint - The report highlights the financial performance and operational developments of Getein Biotech, indicating a decrease in revenue and profit while emphasizing ongoing innovation and market expansion efforts [1][2][3]. Financial Performance - Total assets at the end of the reporting period reached approximately CNY 3.91 billion, an increase of 5.47% compared to the previous year [3]. - Operating revenue for the first half of 2025 was approximately CNY 512.69 million, representing a decrease of 17.00% year-on-year [3]. - Total profit amounted to approximately CNY 110.53 million, down 33.49% from the previous year [3]. - Net profit attributable to shareholders was approximately CNY 93.23 million, a decrease of 28.52% year-on-year [3]. - The cash dividend proposed is CNY 0.9 per 10 shares, accounting for 41.95% of the net profit for the first half of 2025 [2]. Business Operations - The company continues to focus on its core business, with the chemical luminescence segment generating revenue of approximately CNY 150 million, a year-on-year increase of 10.64% [7]. - The company has developed 104 chemical luminescence detection projects, achieving full coverage of common clinical diseases [7]. - The Metis600 and Metis7000 automated biochemical immunoassay lines have been upgraded to enhance efficiency and adaptability for clinical needs [8][9]. - The GN7000/GN7120 automatic nucleic acid amplification analyzers have been launched, achieving significant market penetration with nearly 60 units installed since December 2024 [10]. Innovation and R&D - The company holds a total of 383 patents, including 57 invention patents, indicating a strong focus on innovation [11]. - The introduction of self-developed raw materials has increased the self-sufficiency rate of key materials to over 90% [13]. - The company is committed to expanding its product line and enhancing the performance of existing products to reduce production costs [13]. International Expansion - The company has established product entry permits in 67 countries, with nearly 2800 products approved for import [14]. - The international marketing strategy includes both online and offline channels, enhancing brand recognition and market share [14]. - The company has participated in exhibitions in Dubai and Nigeria, further promoting its global presence [14]. Quality Management - The company adheres to strict quality management standards, aligning with international regulations and certifications [15]. - A comprehensive quality management system has been established, covering all stages from R&D to delivery [15]. - The company has conducted multiple training sessions to enhance the skills of its service team, ensuring high customer satisfaction [16].